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base-case analysis. RESULTS: Base case analysis, resulted in an
ICER of £15,681 per QALY for EVAR versus OSR. The average
QALY gain at 30 years post surgery was 0.072 for EVAR com-
pared with OSR. Results were most sensitive to the relative risk
of short-term mortality, cost of the EVAR device and long-term
rate of secondary interventions in the EVAR group. CONCLU-
SIONS: The results suggest that EVAR is cost-effective for non-
ruptured AAA versus OSR with a probability of 66% and 60%
based on willingness-to-pay thresholds of £30,000 and £20,000,
respectively.
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OBJECTIVES: To determine if clopidogrel plus aspirin is cost-
effective compared to aspirin alone for patients following ACS,
from the Australian health care perspective. METHODS: A
Markov model was constructed by extrapolation of data from
the Australian Acute Coronary Syndromes Prospective Audit
(ACACIA) registry (n = 2553) in the ﬁrst model cycle, and
the Reduction in Atherothrombosis for Continued Health
(REACH) registry (n = 2567 Australian patients) in subsequent
cycles. Decision analysis was applied to compare clopidogrel
plus aspirin against aspirin alone. Efﬁcacy data were drawn
from the Clopidogrel in Unstable Angina to Prevent Recurrent
Events (CURE) trial. A utility study was conducted in 2007
with 86 participants using health states validated by clinical
experts. Drug and disease costs were obtained from literature
and health care reimbursement fees, and updated using Austra-
lian health price indices. An annual discount rate of 5% was
applied to all costs and effects beyond one year in accordance
with reimbursement guidelines. Twenty sensitivity analyses were
undertaken, varying the 95% conﬁdence intervals surrounding
efﬁcacy measures from CURE, uncertainty in cost and utility
inputs and variations to time horizons and discount rates.
RESULTS: The base-case incremental cost-effectiveness ratio
(ICER) with a ten-year time horizon was A$14,496/QALY and
remained below the unofﬁcial cost-effective threshold of
$A40,000/QALY throughout all sensitivity analyses. Treatment
remained cost-effective up to an inﬂated clopidogrel cost of
229%, and even when acute hospitalization costs were removed
(A$20,267/QALY). The ﬁve-year ICER was A$20,124/QALY.
Sensitivity analyses demonstrated that the ICER ranged from
A$6443/QALY when the risk of events observed in ACACIA
were applied to all years, up to A$36,974/QALY using the 95%
upper conﬁdence interval for efﬁcacy. CONCLUSIONS: Clopi-
dogrel with aspirin represents a highly cost-effective treatment
option for patients with ACS in Australia. This was conﬁrmed
by the Australian reimbursement authority’s recent recommen-
dation that treatment with clopidogrel plus aspirin be reim-
bursed for ACS patients.
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OBJECTIVES: Atrial ﬁbrillation is the most common arrhythmia
in the clinical practice. It is related with an important morbidity,
a decrease in patients’ quality of life and is a risk factor of
suffering a stroke. The Spanish estimated atrial ﬁbrillation preva-
lence is 2.52%, and is higher over 60 years. Radiofrequency
surgical ablation is a treatment alternative to restore sinus
rhythm in drug-refractory atrial ﬁbrillation patients. The main
objective of this study is to develop a ﬁve-year cost-utility analy-
sis including the different treatment alternatives in drug-
refractory concomitant atrial ﬁbrillation patients in the Spanish
setting. METHODS: A Markov model was developed to simu-
late the evolution of a 1000 cohort of over 40 years old patients
with paroxistical and persistent atrial ﬁbrillation that could be
treated with: non ablation, surgical ablation and catheter abla-
tion. The model included four heath states: sinus rhythm, atrial
ﬁbrillation, dependent stroke and death. The time horizon was
ﬁve years, with a cycle length of three months. The data of cost
and effects were obtained from the published literature and
experts opinion. Costs and effects were discounted at 3.5%. A
sensibility analysis was developed to determine the robustness of
the main variables of the model. RESULTS: Based on 1000
patients simulation with concomitant atrial ﬁbrillation, prelimi-
nary results show that the QALY gained were 3.79, 4.25, and
4.23, respectively for no ablation, surgical ablation and catheter
ablation. The costs per patient were respectively 8889, 11,157
and 11,865. The cost per QALY gained of the most effectiveness
option (surgical ablation) when compared with no ablation is
€4909. Surgical ablation is a dominant option vs. catheter abla-
tion. CONCLUSIONS: These preliminary results show that
surgical ablation is a cost-effective treatment option in drug
refractory concomitant atrial ﬁbrillation patients in the Spanish
setting, with less cost and a higher efﬁcacy than the catheter
ablation.
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OBJECTIVES: CUA of the use of valsartan when added to
standard treatment in CHF management in Italy. METHODS: A
probabilistic Markov model, made up of states corresponding to
NYHA classes II, III, IV, and death, was developed in WinBUGS
to apply ﬁndings from the Val-HeFT Trial to the Italian setting.
Simulation lasts 10 years, divided in 1-month cycles. Transition
probabilities represent individual mortality, derived from the
general population mortality by gender and age multiplied by a
NYHA state-speciﬁc HR, and probability of changing NYHA
class, derived from Val-HeFT. The model is informed with
NYHA state- and age-speciﬁc utilities and hospitalization prob-
abilities (adjusted for gender and ACEi-use). Costs are calculated
in the perspective of the Italian NHS and account for drugs and
CHF hospitalizations. The cohort was deﬁned to represent
Italian patients with mild-to-severe CHF and LFEV < 40% over
45 years (Val-HeFT inclusion criteria). Results were calculated
through 30,000 iterations of the patient-level simulation (each
individual is created by drawing from age, gender and ACE-I use
distributions of the cohort). Annual discount rate of 3.5% was
applied to costs and health outcomes. Uncertainty around model
parameters was handled by probabilistic sensitivity analysis
(PSA), performed by simultaneous drawing of each model
parameter from the original data source 95% CI, or from the +/-
10% range where original CI was unavailable. RESULTS: On
average, in the simulation timeframe patients live 4.4 years (3.2
QALYs), with a slight increase in the valsartan group, in which
costs are reduced by approximately €500/pt. In subgroup
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